Product Development - Japanese Encephalitis (JE)

SingVax is developing an improved JE vaccine, which will have significant advantages over existing products. SingVax aims to meet the demand in both the endemic and travel markets, for a JE vaccine with improved safety and increased compliance.

SingVax's JE vaccine is based on the inactivated whole JE virus particles. In order to generate the JE viral particles, SingVax leverages upon the PER.C6 ® technology, licensed from Crucell N.V. , a European biotech company. SingVax has also partnered with OctoPlus to co-develop a single-shot JE vaccine.

Next

  

 


Due to limitations of the existing vaccine, there is a significant market potential for a JE vaccine, estimated at US$250 million.